Comparison of Imaging Changes and Pain Responses in Patients with Intra- or Extraosseous Bone Metastases Treated Palliatively with Magnetic Resonance-Guided High-Intensity-Focused Ultrasound.
Loading...
Embargo End Date
ICR Authors
Authors
Giles, SL
Brown, MRD
Rivens, I
Deppe, M
Huisman, M
Kim, Y-S
Farquhar-Smith, P
Williams, JE
Ter Haar, GR
deSouza, NM
Brown, MRD
Rivens, I
Deppe, M
Huisman, M
Kim, Y-S
Farquhar-Smith, P
Williams, JE
Ter Haar, GR
deSouza, NM
Document Type
Journal Article
Date
2019-02-21
Date Accepted
2019-02-21
Abstract
PURPOSE: This study compared changes in imaging and in pain relief between patients with intraosseous, as opposed to extraosseous bone metastases. Both groups were treated palliatively with magnetic resonance-guided high-intensity-focused ultrasound (MRgHIFU). MATERIALS AND METHODS: A total of 21 patients were treated prospectively with MRgHIFU at 3 centers. Intraprocedural thermal changes measured using proton resonance frequency shift (PRFS) thermometry and gadolinium-enhanced T1-weighted (Gd-T1W) image appearances after treatment were compared for intra- and extraosseous metastases. Pain scores and use of analgesic therapy documented before and up to 90 days after treatment were used to classify responses and were compared between the intra- and extraosseous groups. Gd-T1W changes were compared between responders and nonresponders in each group. RESULTS: Thermal dose volumes were significantly larger in the extraosseous group (P = 0.039). Tumor diameter did not change after treatment in either group. At day 30, Gd-T1W images showed focal nonenhancement in 7 of 9 patients with intraosseous tumors; in patients with extraosseous tumors, changes were heterogeneous. Cohort reductions in worst-pain scores were seen for both groups, but differences from baseline at days 14, 30, 60, and 90 were only significant for the intraosseous group (P = 0.027, P = 0.013, P = 0.012, and P = 0.027, respectively). By day 30, 67% of patients (6 of 9) with intraosseous tumors were classified as responders, and the rate was 33% (4 of 12) for patients with extraosseous tumors. In neither group was pain response indicated by nonenhancement on Gd-T1W. CONCLUSIONS: Intraosseous tumors showed focal nonenhancement by day 30, and patients had better pain response to MRgHIFU than those with extraosseous tumors. In this small cohort, post-treatment imaging was not informative of treatment efficacy.
Citation
Journal of vascular and interventional radiology : JVIR, 2019, 30 (9), pp. 1351 - 1360.e1
Source Title
Publisher
ELSEVIER SCIENCE INC
ISSN
1051-0443
eISSN
1535-7732
Collections
Research Team
Magnetic Resonance
Therapeutic Ultrasound
Therapeutic Ultrasound